OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS

E-ISSN： 1471-6348|32|6|385-392

ISSN： 0266-4623

Source： International Journal of Technology Assessment in Health Care, Vol.32, Iss.6, 2017-01, pp. : 385-392

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-effective osteoporosis treatment thresholds: the United States perspective

By Tosteson A. Melton L. Dawson-Hughes B. Baim S. Favus M. Khosla S. Lindsay R.

Osteoporosis International, Vol. 19, Iss. 4, 2008-04 ,pp. : 437-447

Springer Publishing Company

Access to resources Recommend Favorite

Generic medication utilization policies

JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH (ELECTRONIC), Vol. 6, Iss. 1, 2015-03 ,pp. : 3-10

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dynamic competition in pharmaceuticals: Patent expiry, generic penetration, and industry structure

By Magazzini Laura Pammolli Fabio Riccaboni Massimo

The European Journal of Health Economics, Vol. 5, Iss. 2, 2004-05 ,pp. : 175-182

Springer Publishing Company

Access to resources Recommend Favorite

Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 5, 2015-05 ,pp. : 508-517

John Wiley & Sons Inc

Access to resources Recommend Favorite

Side effects of generic competition?

By Hellström Jörgen Rudholm Niklas

The European Journal of Health Economics, Vol. 5, Iss. 3, 2004-09 ,pp. : 203-208

Springer Publishing Company

Access to resources Recommend Favorite